CARS1 and neoplasm: This is called adoptive cell therapy (Rosenberg et al., 2008; Perica et al., 2015) and can be divided into two subtypes: adoptive tumor-infiltrating lymphocytes (TILs) and genetically engineered T cells expressing specific T cell receptors (TCRs) or chimeric antigen receptors (CARs).